Physician profile
Carmine V Oddis
NPI 1659315737
$17,700.91
in general payments reported to CMS, 2019-2025
31 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what a typical Nuclear Radiology provider received nationally (typical 2025 total: $145).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $1,490 · 2021: $2,711 · 2022: $6,229 · 2023: $1,731 · 2024: $2,078 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,947 · Travel and Lodging: $399 · Education: $35.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,946.70 |
| Travel and Lodging | $398.99 |
| Education | $35.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,500.92 | 2019-2025 | Aveir, Ensite, Advisor |
| Novartis Pharmaceuticals Corporation | $2,022.02 | 2019-2024 | |
| Pfizer INC. | $1,417.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,098.39 | 2019-2024 | Xarelto |
| Medtronic, INC. | $823.17 | 2021-2025 | Affera Mapping System, Na, Flexcath Advance |
| Medtronic Vascular, INC. | $580.03 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $540.04 | 2019-2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $499.89 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $498.71 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $475.52 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $389.79 | 2019-2025 | Watchman Flx, Rhythmia Mapping System, Farapulse |
| Cardiva Medical, INC. | $341.71 | 2019-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Bayer Healthcare Pharmaceuticals INC. | $327.62 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $197.70 | 2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.12 | 2019-2025 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $158.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.09 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $104.24 | 2025 | Assure Wcd |
| Amgen INC. | $89.54 | 2019-2025 | Repatha |
| Cordis US Corp. | $64.38 | 2024-2025 | Mynx Control |
| Cvrx, INC. | $44.10 | 2024 | Barostim Neo System |
| Philips North America LLC | $42.76 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $31.24 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $29.57 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $27.26 | 2020-2021 | |
| Edwards Lifesciences Corporation | $20.02 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| United Therapeutics Corporation | $14.15 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.64 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.36 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $5.99 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmine Oddis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.